Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark
出版年份 2015 全文链接
标题
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark
作者
关键词
-
出版物
OncoImmunology
Volume 4, Issue 7, Pages e1058037
出版商
Informa UK Limited
发表日期
2015-06-04
DOI
10.1080/2162402x.2015.1058037
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma
- (2014) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2014) Jonathan Pol et al. OncoImmunology
- A novel combinatorial cancer immunotherapy
- (2014) Toshihiro Nagato et al. OncoImmunology
- Co-blockade of immune checkpoints and adenosine A2Areceptor suppresses metastasis
- (2014) Arabella Young et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Trial watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
- (2014) Zachary A Cooper et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade
- (2014) Janis M Taube OncoImmunology
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
- (2014) Lidia Robert et al. OncoImmunology
- Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level
- (2013) James L. Riley NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Current trends of anticancer immunochemotherapy
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Inhibiting the inhibitors
- (2013) Domenico Mavilio et al. OncoImmunology
- Endogenous tumor-reactive CD8+T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth
- (2013) Xin Liu et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now